Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation, Single Center, Open-Label Study of AUY922 Administered IV on a Once-Weekly Schedule in Adult Patients 75 Years of Age or Older With Advanced Solid Malignancies

NCT01602627 is registered in ClinicalTrials.gov with Dale Shepard, MD, PhD as lead sponsor.

NCT NCT01602627
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01602627 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation, Single Center, Open-Label Study of AUY922 Administered IV on a Once-Weekly Schedule in Adult Patients 75 Years of Age or Older With Advanced Solid Malignancies
Lead sponsor
Dale Shepard, MD, PhD
Phase
Phase 1
Overall status
Terminated
Start date
September 30, 2011
Completion date
February 29, 2012
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

unspecified adult solid tumor, protocol specific